EyePoint Pharmaceuticals recently announced results of the Phase 1 Clinical Trial of their new wet age-related macular degeneration treatment, EYP-1901.
The trial had 17 patients who received one of three doses of the injection, which is a Durasert sustained-release technology with vorolanib. The drug is administered twice a year via intravitreal injection.
The 30 days of post-administration follow up had no serious adverse reactions reported by study participants. No adverse events associated with intraocular inflammation, reduced visual acuity or elevated intraocular pressure. fEyePoint will release interim efficacy results for all dose cohorts in the fourth quarter of this year.
For patients who have the dry form of macular degeneration, VisiVite offers several macular degeneration formulas based on the Age-Related Eye Disease Studies.
